The effect of the somatostatin analogue octreotide on the secretion of progesterone and insulin-like growth factor binding protein-1 (IGFBP-1) from human granulosa-luteal cells was investigated. Octreotide (10 -11 , 10 -10 and 10 -9 M) alone induced a significant decrease in progesterone secretion (maximum suppression 69 ⍨ 5% of control: P < 0.0001). In contrast, treatment with octreotide in combination with human chorionic gonadotrophin (HCG), at 1 IU/ ml potentiated the stimulatory effect of HCG on progesterone secretion (HCG alone 201 ⍨ 3% of control: HCG ϩ octreotide 10 -9 M 318 ⍨ 16%: P < 0.001). Treatment with octreotide increased the secretion of IGFBP-1 (maximum stimulation 254 ⍨ 25% of control: P Ͻ 0.01). No effect of HCG was seen on secretion of IGFBP-1. These findings raise the possibility that somatostatin may have a modulatory role in regulating steroidogenesis by the human corpus luteum. Further studies are required to establish the physiological significance of any such function.
Introduction
Somatostatin is a 14 amino acid peptide which is secreted from the hypothalamus into the portal circulation to inhibit growth hormone secretion by the anterior pituitary (Brazeau et al., 1973) . However, somatostatin has also been demonstrated to have biological activities at a number of other sites including the central nervous system, the hypothalamus, the gastrointestinal tract and the pancreas (Reichlin, 1983; Schusdziarra, 1983; Lamberts, 1988) . In the hypothalamo-pituitary-ovarian tract, somatostatin has been demonstrated to reduce the circulating concentrations of luteinizing hormone (LH) with little effect on follicle stimulating hormone (FSH) concentration (Prelevic et al., 1990) .
Somatostatin immunoreactivity has been demonstrated in the ovaries of a number of species, with particular immunostaining found in the granulosa cells (Mori et al., 1984; McIntyre et al., 1992) . In women, the concentration of somatostatin in follicular fluid was found to be higher than that in the circulation,
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© European Society for Human Reproduction and Embryology and in addition, exhibited a positive association with the concentration of progesterone (Holst et al., 1994) . However, preprosomatostatin mRNA has not been identified in the ovary (McIntyre et al., 1992) , suggesting that the increased concentrations found in follicular fluid represent accumulation of somatostatin rather than de-novo synthesis.
The possibility thus arises that somatostatin may have a modulatory role within the ovary. Addition of somatostatin to cultured human luteinized granulosa cells has previously been shown to affect progesterone secretion by these cells (Holst et al., 1995) . One possible mechanism for somatostatin action in the ovary would be through modulation of the activity of insulin-like growth factor I (IGF-I) via changes in the amounts of IGF-binding protein 1 (IGFBP-1). IGF-I enhances steroidogenesis in both granulosa and thecal cells (Giudice, 1992) , as well as promoting DNA synthesis, an effect which is inhibited by excess concentrations of IGFBP-1 (Angervo et al., 1991) . Although IGFBP-1 is undetectable in follicular fluid from immature human follicles, it has been identified in mature follicles following human chorionic gonadotrophin (HCG) administration (Seppala et al., 1984; Adashi et al., 1991) . Somatostatin has been found to stimulate IGFBP-1 synthesis in a number of tissues but the effects on IGFBP-1 synthesis in the ovary are unknown.
This study therefore aims to investigate the effects of somatostatin on the human ovary by studying the secretion of progesterone and IGFBP-1 in response to octreotide (a potent analogue of somatostatin).
Materials and methods

Granulosal cell culture
Granulosal cells were obtained by the aspiration of pre-ovulatory follicles from women undergoing oocyte retrieval for in vitro fertilization (IVF) or gamete intra-Fallopian transfer (GIFT) at Westmead Fertility Centre. These women underwent a standard ovarian stimulation regime involving pretreatment with GnRH agonist (Lucrin; Abbott, Kurnell, NSW, Australia) using a long downregulation protocol, followed by stimulation with human menopausal gonadotrophin (HMG; Humegon, Organon, Sydney, Australia). When at least three follicles had reached ജ16 mm in diameter, ovulation was induced with 5000 IU HCG (Pregnyl, Organon), and transvaginal oocyte aspiration performed 35 h later. Informed consent was obtained from all subjects. Ethical approval was given for these studies by the Western Sydney Area Health Service Ethics of Human Research Committee.
Cells from an individual patient were collected from follicular fluid by centrifugation and resuspended in 1 ml Dulbecco's Modified Eagle's Medium: Ham's F12 (1:1 vol/vol) containing 15 mM HEPES and 36.5 mg L-glutamine (Sigma Aldrich Ltd, Sydney, Australia).
The cell suspension was layered onto a 7 ml discontinuous gradient, which consisted of 1 ml steps of the above medium with 10-70% Percoll (vol/vol) (Pharmacia Biotech, Uppsala, Sweden) in 10% increments. The gradient was centrifuged at 1200 g for 20 min. This procedure separated red cells from an upper layer of granulosa cells. The granulosa cells were collected, washed twice and resuspended to a density of 50 000 cells/ml in the fresh medium supplemented with 10% fetal cow serum (FCS) (CSL Biosciences, Parkville, Victoria, Australia), 50 IU/ml penicillin, and 50 µg/ml streptomycin (ICN Biomedicals Inc., Costa Mesa, CA, USA). The viability of cells, as assessed by trypan blue staining, was 90%. Aliquots of 1 ml of the suspension were transferred to each well of a 24-well culture dish (Falcon, Franklin Lakes, NJ, USA) and the dishes incubated overnight at 37°C, 5% CO 2 and 95% humidity to allow attachment.
Experimental design
After an initial culture period of 48 h, a medium change was carried out and the supplemented medium replaced with serum-free medium for 24 h. Subsequently, this serum-free medium was replaced with medium containing the varying concentrations of octreotide (Sandostatin; Sandoz, Switzerland) (10 -11 , 10 -10 , 10 -9 M) in both the presence and absence of HCG (1 IU/ml) (Pregnyl, Organon, Netherlands).
In order to investigate the timing of any effects observed the medium was collected after varying durations of culture (3, 6, 24 and 48 h) and stored at -20°C for assay. IGFBP-1 was measured in the 48 h medium only. At the end of incubation the cell viability was reassessed and found to be greater than 80% in all experiments.
Assays
The concentrations of IGFBP-1 in medium were measured by an enzyme immunoassay kit kindly provided by Medix Biochemica (Kauniainen, Finland). This IGFBP-1 immunoradiometric assay is a two-step assay for measurement of human IGFBP-1 using antibodies raised against purified IGFBP-1 (Rutanen and Pekonen, 1991) . The sensitivity of the assay was 0.4 µg/l, and within-assay and betweenassay coefficients of variation were 2.8 and 6.2% respectively.
Progesterone content in the culture medium was measured by chemiluminescent enzyme immunoassay (Immulite; DPC, Los Angeles, CA, USA) after suitable dilution of the incubation medium. This assay has a sensitivity of 0.3 nmol/l, with within-assay and between-assay coefficients of variation of 6.9 and 8.1% respectively.
Statistical analyses
Each data set shown is the summary of five experiments each performed in triplicate. The results were evaluated statistically by one-way and two-way analysis of variance (ANOVA) of the whole data set, taking treatment with somatostatin and HCG as independent within-subject variables. Statistical significance was assumed at P Ͻ 0.05. Results are expressed either in absolute concentrations (mean Ϯ SE) in the figures or as a percentage of the concentration found in untreated cells from the same experiments, in the results section.
Results
The progesterone concentrations in the medium after different durations of culture are shown in Figure 1 . The progesterone concentration in the medium increased steadily with time of culture. HCG exerted a consistent effect on all cell cultures, which was most apparent after 48 h of culture, where the mean progesterone concentration expressed as a percentage of the progesterone concentration in the untreated cells was 201 Ϯ 3% (overall effect of HCG: P Ͻ 0.001).
Treatment of the cultured granulosa cells with octreotide alone induced a significant decrease in progesterone secretion (Figure 2 ) at all the time points studied. The maximum degree of suppression (69 Ϯ 5% of control: P Ͻ 0.0001) was found after 6 h with 10 -9 M octreotide. After 24 h, progesterone secretion was suppressed to the following levels: 10 -9 M, 70 Ϯ 4% of control; 10 -10 M, 76 Ϯ 6% of control; 10 -11 M, 86 Ϯ 6% of control (overall effect of somatostatin P Ͻ 0.0001). The inhibitory effect occurred in a dose-dependent manner and these effects were continued until 48 h.
In contrast, treatment with octreotide in combination with HCG (1 IU/ml) led to significant potentiation of the effect of HCG in a dose dependent manner, at all time points studied (Figure 2) . The stimulatory effects of octreotide were observed at an earlier stage compared with the effect of HCG alone. A significant stimulatory effect (10 -9 M, 207 Ϯ 38% of control, 10 -10 M, 182 Ϯ 20% of control, 10 -11 M, 169 Ϯ 17% of control, HCG alone, 131 Ϯ 20% of control; overall effect of somatostatin P Ͻ 0.001) was found after only 3 h incubation. After 48 h, the stimulatory effect of octreotide was still apparent, as follows: 10 -9 M, 318 Ϯ 16%; 10 -10 M, 272 Ϯ 15% of control; 10 -11 M, 265 Ϯ 15% of control; HCG alone, 201 Ϯ 3% of control: overall effect of somatostatin P Ͻ 0.001. Two-way analysis of variance revealed a significant interaction between the effects of HCG and octreotide (P Ͻ 0.001).
The IGFBP-1 concentration in the medium after 48 h incubation was found to be unchanged by treatment with HCG (132 Ϯ 9% of control) (Figure 3) . A significant increase in concentration was noted in response to treatment with increasing doses of octreotide alone (10 -9 M, 253 Ϯ 25%; 10 -10 M, 211 Ϯ 20%; 10 -11 M, 153 Ϯ 17%; overall effect of octreotide P Ͻ 0.01) When treatment with octreotide was given in combination with HCG, a similar increase was found compared with HCG alone [10 -9 M, 234 Ϯ 19% of control; 10 -10 M, 209 Ϯ 16% of control; 10 -11 M, 160 Ϯ 14% of control (overall effect of octreotide P Ͻ 0.001)]. No significant Figure 2 . Progesterone concentrations in culture medium collected from human luteinizing granulosa cells after 3, 6, 24 and 48 h with different treatment concentrations of octreotide (10 -11 -10 -9 M) (ϮHCG) added. Results are expressed as mean Ϯ SE. Effects of octreotide: ****P Ͻ 0.0001; ***P Ͻ 0.001; **P Ͻ 0.01; *P Ͻ 0.05. interaction was observed between treatment with HCG and octreotide on the concentration of IGFBP-1.
Discussion
These data demonstrate a clear effect of octreotide on progesterone secretion by human luteinizing granulosa cells in culture. When octreotide was added alone, significant inhibition of progesterone secretion was observed. However, in contrast, when octreotide was added in combination with HCG, a significant potentiation of the stimulatory effect of HCG was observed. These apparently paradoxical findings are in agreement with previous observations (Holst et al., 1995) , although other workers have reported either no effect (Pawelczyk et al., 1993) or an inhibitory effect (Andreanni et al., 1995) on ovarian steroidogenesis. These differences may suggest that the effect of somatostatin is specific for luteinized granulosa cells and has no effect on immature unluteinized follicles. In addition, as it was previously found that somatostatin has no effect on secretion of testosterone or oestradiol by luteinized granulosa cells (Pawelczyk et al., 1993) , the effect of somatostatin may relate solely to the steroidogenic pathway leading to progesterone synthesis.
We were able to demonstrate the presence of IGFBP-1 in the medium from the luteinized granulosa cells. IGFBP-1 mRNA expression and immunolocalization has been demonstrated in human ovarian granulosa Koistinen et al., 1990; Ehrenborg et al., 1992) . Small amounts of IGFBP-1 protein have been detected in the human ovary, localized to the luteinized granulosa cells of the corpus luteum and hyperstimulated follicles, but not in preovulatory, nonluteinized follicles (Seppala et al., 1984; Adashi et al., 1991) . This suggests that IGFBP-1 plays little role in the function of the preovulatory follicle and is only present following ovulation when the principal secretory product is progesterone.
IGFBP-1 concentrations were very low in the medium, but octreotide caused a significant increase in IGFBP-1 concentration in a dose dependent manner while HCG exerted no effect. It has previously been reported that octreotide increased the circulating concentrations of both IGFBP-1 and 3 in healthy subjects Wolthers et al., 1994) and women with polycystic ovary syndrome (Morris et al., 1995) . In addition, in-vitro studies have demonstrated that somatostatin increases IGFBP-1 secretion by hepatoma cells . Jalkanen et al. (1989) have previously studied the regulation of IGFBP-1 secretion by cultured human granulosaluteal cells.
HCG did not affect IGFBP-1 secretion by the granulosa cells. HCG acts primarily via a cAMP-mediated second messenger system (Jalkanen et al., 1986) , while IGFBP-1 concentrations are significantly stimulated by phorbol ester and prostaglandin E 2 , implying different regulatory mechanisms .
What is the physiological significance of these data? These data raise the possibility that somatostatin may effect a modulatory role by inhibiting steroidogenesis in the absence of HCG (e.g. during luteolysis) while enhancing steroidogenesis in the presence of HCG (e.g. in early pregnancy). The mechanism by which this bidirectional effect on progesterone synthesis is brought about is unknown. One possibility is that steroidogenesis may be inhibited through enhanced synthesis of IGFBP-1. IGFBP-1 in excess concentrations results in reduced IGF-I action at the tissue level (Angervo et al., 1991) and is likely to be an important modulator of local IGF-I bioactivity. IGF-I is an important paracrine regulator of granulosa cell function (Giudice, 1992) and if IGFBP-1 has a role in modulating steroidogenesis, this offers a potential mechanism to explain the effects of somatostatin on steroidogenesis. However, the enhanced secretion of IGFBP-1 despite the presence of HCG is puzzling. In summary, we have confirmed the work of others in demonstrating a significant effect of somatostatin on both steroidogenesis and IGFBP-1 secretion. However, further in vivo studies are required to assess the physiological significance of these in vitro experiments in the regulation of steroidogenesis in the human ovary.
